Literature DB >> 8627055

Neutralization of human cytomegalovirus by human CD13-specific antibodies.

T D Giugni1, C Söderberg, D J Ham, R M Bautista, K O Hedlund, E Möller, J A Zaia.   

Abstract

The mechanisms of inhibition of cytomegalovirus (CMV) infection by human CD13 (aminopeptidase N)-specific antibodies were studied. These antibodies protect CD13-negative and -positive cells from CMV infection only if incubated with the virus inoculum, suggesting they bind to CMV virions. The association of a CD13-like molecule with virions was further supported by the transfer of CD13 immunoreactivity to the surface of CD13-negative cells upon binding of CMV; the binding of CD13-specific antibodies directly to the surface of CMV virions; and the presence of anti-CD13 immunoreactive bands, including one with mobility similar to that of native cellular CD13 on immunoblots of proteins of purified CMV particles. Importantly, CD13-specific antibodies neutralize CMV in urine of neonates with congenital CMV, indicating that the CD13-like molecule is associated with natural CMV and not acquired in vitro. These studies demonstrate that a CD13-like molecule is associated with CMV particles and may be important in CMV pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627055      PMCID: PMC7110010          DOI: 10.1093/infdis/173.5.1062

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): influence of N-linked glycosylation.

Authors:  D E Wentworth; K V Holmes
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  A targeted approach to the identification of candidate genes determining susceptibility to Plasmodium gallinaceum in Aedes aegypti.

Authors:  I Morlais; A Mori; J R Schneider; D W Severson
Journal:  Mol Genet Genomics       Date:  2003-09-25       Impact factor: 3.291

3.  Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome.

Authors:  Susan M Varnum; Daniel N Streblow; Matthew E Monroe; Patricia Smith; Kenneth J Auberry; Ljiljana Pasa-Tolic; Dai Wang; David G Camp; Karin Rodland; Steven Wiley; William Britt; Thomas Shenk; Richard D Smith; Jay A Nelson
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

4.  Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031.

Authors:  G D E Cuvelier; A Kariminia; H Fujii; S Aslanian; D Wall; F Goldman; S A Grupp; S E Dunn; M Krailo; L H Shapiro; A Gilman; K R Schultz
Journal:  Bone Marrow Transplant       Date:  2010-03-01       Impact factor: 5.483

5.  Human cytomegalovirus entry into dendritic cells occurs via a macropinocytosis-like pathway in a pH-independent and cholesterol-dependent manner.

Authors:  Fabienne Haspot; Amélie Lavault; Christian Sinzger; Kerstin Laib Sampaio; York-Dieter Stierhof; Paul Pilet; Céline Bressolette-Bodin; Franck Halary
Journal:  PLoS One       Date:  2012-04-09       Impact factor: 3.240

6.  Proteomic analyses of human cytomegalovirus strain AD169 derivatives reveal highly conserved patterns of viral and cellular proteins in infected fibroblasts.

Authors:  Sabine Reyda; Nicole Büscher; Stefan Tenzer; Bodo Plachter
Journal:  Viruses       Date:  2014-01-07       Impact factor: 5.048

7.  Inhibitory effect of anti-aminopeptidase N/CD13 antibodies on fibroblast migration.

Authors:  Amy Lai; Abdi Ghaffari; Aziz Ghahary
Journal:  Mol Cell Biochem       Date:  2010-06-30       Impact factor: 3.396

8.  The activation-dependent induction of APN-(CD13) in T-cells is controlled at different levels of gene expression.

Authors:  T Wex; F Bühling; M Arndt; K Frank; S Ansorge; U Lendeckel
Journal:  FEBS Lett       Date:  1997-07-21       Impact factor: 4.124

9.  An improved procedure for the generation of recombinant single-chain Fv antibody fragments reacting with human CD13 on intact cells.

Authors:  M Peipp; N Simon; A Loichinger; W Baum; K Mahr; S J Zunino; G H Fey
Journal:  J Immunol Methods       Date:  2001-05-01       Impact factor: 2.303

Review 10.  The moonlighting enzyme CD13: old and new functions to target.

Authors:  Paola Mina-Osorio
Journal:  Trends Mol Med       Date:  2008-07-05       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.